Zevra SVP Sangiovanni Sells Shares, Settles RSUs

Zevra Therapeutics SVP Timothy J. Sangiovanni reported stock transactions involving common shares and restricted stock units.

Rhea-AI Filing Summary

Zevra Therapeutics SVP Timothy J. Sangiovanni reported stock transactions involving common shares and restricted stock units. On January 30, 2026, he settled 6,333 restricted stock units into common stock and sold 1,750 shares at a weighted average price of $8.824 under a pre-arranged Rule 10b5-1(c) trading plan adopted on March 28, 2025.

On January 31, 2026, he settled another 11,666 restricted stock units into common stock. Following these transactions, he directly beneficially owned 32,590 shares of common stock and held remaining restricted stock units that continue to vest over time, subject to his continued service.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Sangiovanni Timothy J.

Role SVP, Finance & Corp Controller

Sold 1,750 shs ($15K)

Approx. gross sale proceeds $15K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	11,666	$0.00	$0.00
Exercise	Common Stock	11,666	$0.00	$0.00
Exercise	Restricted Stock Unit	6,333	$0.00	$0.00
Exercise	Common Stock	6,333	$0.00	$0.00
Sale	Common Stock	1,750	$8.824	$15K

Holdings After Transaction: Restricted Stock Unit — 24,335 contracts (Direct); Common Stock — 32,590 shares (Direct)

Footnotes (5)

1. F1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
2. F2. Adoption date of referenced 10b5-1(c) plan is: 3/28/2025.
3. F3. This transaction was executed in multiple trades at prices ranging from $8.62 to $8.995. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
4. F4. One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the shares will vest and settle in equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date.
5. F5. One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject to the Reporting person's continued service through such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ZVRA executive Timothy Sangiovanni report?

Timothy Sangiovanni reported settling restricted stock units into common shares and selling stock. He exercised 6,333 and 11,666 restricted stock units on January 30–31, 2026, and sold 1,750 common shares on January 30, 2026, at a weighted average price of $8.824.

How many Zevra Therapeutics (ZVRA) shares does the SVP hold after these trades?

After the reported transactions, Timothy Sangiovanni beneficially owned 32,590 shares of Zevra Therapeutics common stock directly. This figure reflects the net result of restricted stock unit settlements and the 1,750-share sale disclosed for January 30–31, 2026.

Were the ZVRA insider stock sales made under a Rule 10b5-1 trading plan?

Yes. The 1,750-share sale on January 30, 2026, was made under a Rule 10b5-1(c) trading plan. The filing notes the plan’s adoption date as March 28, 2025, indicating the sale followed a pre-established trading arrangement.

What price did the ZVRA insider receive for the sold shares?

The 1,750 common shares sold on January 30, 2026, were executed in multiple trades between $8.62 and $8.995. The reported weighted average sale price was $8.824 per share, as disclosed in the transaction footnote.

How do the restricted stock units for ZVRA’s SVP vest over time?

One restricted stock unit grant vested one-third on January 30, 2026, with the remaining two-thirds vesting in equal annual installments thereafter. Another grant vested one-third on January 31, 2025, one-third on January 31, 2026, and the final third is scheduled for January 31, 2027.

What role does Timothy Sangiovanni hold at Zevra Therapeutics (ZVRA)?

Timothy J. Sangiovanni serves as Senior Vice President, Finance & Corporate Controller at Zevra Therapeutics. His Form 4 filing reflects equity compensation activity and a stock sale consistent with his status as an officer of the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 05:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sangiovanni Timothy J.

(Last) (First) (Middle)

C/O ZEVRA THERAPEUTICS, INC.

1180 CELEBRATION BOULEVARD, SUITE 103

(Street)

CELEBRATION FL 34747

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance & Corp Controller

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		M		6,333	A	(1)	22,674	D
Common Stock	01/30/2026		S(2)		1,750	D	$8.824(3)	20,924	D
Common Stock	01/31/2026		M		11,666	A	(1)	32,590	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	01/30/2026		M			6,333	(4)	(4)	Common Stock	6,333	$0	12,667	D
Restricted Stock Unit	(1)	01/31/2026		M			11,666	(5)	(5)	Common Stock	11,666	$0	11,668	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

2. Adoption date of referenced 10b5-1(c) plan is: 3/28/2025.

3. This transaction was executed in multiple trades at prices ranging from $8.62 to $8.995. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

4. One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the shares will vest and settle in equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date.

5. One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject to the Reporting person's continued service through such vesting date.

Remarks:

	/s/ Timothy J. Sangiovanni	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.